HARMONY BIOSCIENCES HLDGS IN's ticker is HRMY and the CUSIP is 413197104. A total of 60 filers reported holding HARMONY BIOSCIENCES HLDGS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,227,030 | -10.0% | 434,148 | -3.3% | 2.09% | -5.2% |
| Q2 2023 | $15,801,647 | +8.7% | 449,038 | +0.8% | 2.21% | +1.4% |
| Q1 2023 | $14,542,898 | -26.0% | 445,418 | +24.9% | 2.18% | -28.6% |
| Q4 2022 | $19,650,754 | -9.6% | 356,638 | -27.3% | 3.05% | -8.1% |
| Q3 2022 | $21,736,000 | -33.2% | 490,768 | -26.4% | 3.32% | -28.3% |
| Q2 2022 | $32,542,000 | +1.4% | 667,248 | +1.1% | 4.62% | +33.7% |
| Q1 2022 | $32,103,000 | +8.4% | 659,873 | -5.0% | 3.46% | +17.1% |
| Q4 2021 | $29,626,000 | +22.6% | 694,783 | +10.2% | 2.95% | +34.5% |
| Q3 2021 | $24,166,000 | +34.2% | 630,473 | -1.2% | 2.20% | +35.1% |
| Q2 2021 | $18,012,000 | -15.7% | 638,033 | -1.3% | 1.62% | -18.6% |
| Q1 2021 | $21,366,000 | +116.5% | 646,673 | +136.9% | 2.00% | +109.0% |
| Q4 2020 | $9,867,000 | – | 272,950 | – | 0.96% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Valor Management LLC | 11,218,033 | $618,113,619 | 97.50% |
| venBio Partners LLC | 1,035,396 | $57,050,320 | 17.69% |
| Vivo Capital, LLC | 2,606,247 | $143,604 | 16.53% |
| Nan Fung Group Holdings Ltd | 368,665 | $20,313,442 | 14.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 264,500 | $14,560,725 | 4.50% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 685,340 | $37,762,234 | 3.51% |
| ASHFORD CAPITAL MANAGEMENT INC | 356,638 | $19,650,754 | 3.05% |
| TANG CAPITAL MANAGEMENT LLC | 281,200 | $15,494,120 | 2.25% |
| MPM BioImpact LLC | 139,377 | $7,679,673 | 1.99% |
| O'Neil Global Advisors, Inc. | 7,335 | $404 | 1.86% |